CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185
Debt
Debt-to-Equity RatioN/A
Current Ratio4.41
Quick Ratio4.41
Price-To-Earnings
Trailing P/E Ratio-19.51
Forward P/E Ratio-15.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.62 million
Price / Sales14.21
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book12.43
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-44.46%
Return on Equity-74.84%
Return on Assets-10.03%
Miscellaneous
Employees93
Outstanding Shares44,960,000
Market Cap$1.09 billion
CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
How were CytomX Therapeutics' earnings last quarter?
CytomX Therapeutics Inc (NASDAQ:CTMX) announced its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The biotechnology company had revenue of $21.34 million for the quarter, compared to analysts' expectations of $16.48 million. CytomX Therapeutics had a negative net margin of 44.46% and a negative return on equity of 74.84%. View CytomX Therapeutics' Earnings History.
When is CytomX Therapeutics' next earnings date?
What price target have analysts set for CTMX?
9 brokers have issued twelve-month price targets for CytomX Therapeutics' shares. Their predictions range from $37.00 to $44.00. On average, they anticipate CytomX Therapeutics' stock price to reach $39.8571 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics.
What is the consensus analysts' recommendation for CytomX Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics.
Who are some of CytomX Therapeutics' key competitors?
Some companies that are related to CytomX Therapeutics include HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA) and Amicus Therapeutics (FOLD).
Who are CytomX Therapeutics' key executives?
CytomX Therapeutics' management team includes the folowing people:
- Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
- Mr. Debanjan Ray, CFO & Head of Corp. Devel. (Age 40)
- Dr. Rachel Wallach Humphrey, Chief Medical Officer (Age 57)
- Dr. W. Michael Kavanaugh, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
- Ms. Danielle Olander, Sr. VP of Talent & Admin. Operations
Has CytomX Therapeutics been receiving favorable news coverage?
Media coverage about CTMX stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CytomX Therapeutics earned a media and rumor sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.50 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for CytomX Therapeutics.
Who are CytomX Therapeutics' major shareholders?
CytomX Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (8.28%), Renaissance Technologies LLC (3.14%), Aquilo Capital Management LLC (1.45%), Millennium Management LLC (0.59%) and Redmile Group LLC (0.58%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Ix LP Canaan, Kevin P Starr, Rachel Humphrey, Robert C Goeltz II, Robert I Tepper, Rock Ventures Lp Third, Sean A Mccarthy, Timothy M Shannon and William Michael Kavanaugh. View Institutional Ownership Trends for CytomX Therapeutics.
Which major investors are selling CytomX Therapeutics stock?
CTMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC, Bank of America Corp DE, Russell Investments Group Ltd., American Century Companies Inc., Spark Investment Management LLC, Citadel Advisors LLC and Acadian Asset Management LLC. Company insiders that have sold CytomX Therapeutics company stock in the last year include Debanjan Ray, Frederick W Gluck, Rachel Humphrey, Robert I Tepper, Sean A Mccarthy and William Michael Kavanaugh. View Insider Buying and Selling for CytomX Therapeutics.
Which major investors are buying CytomX Therapeutics stock?
CTMX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Aquilo Capital Management LLC, Renaissance Technologies LLC, Private Advisor Group LLC, Point72 Asset Management L.P., First Trust Advisors LP, HarbourVest Partners LLC and FMR LLC. View Insider Buying and Selling for CytomX Therapeutics.
How do I buy shares of CytomX Therapeutics?
Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CytomX Therapeutics' stock price today?
One share of CTMX stock can currently be purchased for approximately $22.63.
How big of a company is CytomX Therapeutics?
CytomX Therapeutics has a market capitalization of $1.09 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.
How can I contact CytomX Therapeutics?
CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]
MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
